Akari Therapeutics, Plc (NASDAQ:AKTX) is a biotechnology company that focuses on developing treatments for oncology. The company is preparing for a significant change in its stock structure. On March 31, 2026, AKTX will implement a reverse stock split, exchanging 1 share for every 40 shares. This move is part of a broader strategy to maintain compliance with Nasdaq's listing requirements.In addition to the reverse stock split, Akari is adjusting the ratio of its American Depositary Shares (ADSs) to ordinary ...

TAMPA, Fla. and LONDON, March 18, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splice modulating payloads, today announced its abstract has been accepted for poster presentation at the American Association for Cancer Research Annual Meeting 2026, being held April 17–22, 2026. Details of the poster presentation are as follows: Title: Rationale for the development of a differentiated Trop2 ADC in so ...

Core Insights - The article discusses the recent financial performance of a leading technology company, highlighting a significant increase in revenue and net income compared to the previous year [1] Financial Performance - The company reported a revenue of $50 billion for the last quarter, representing a 20% increase year-over-year [1] - Net income reached $10 billion, which is a 25% increase compared to the same quarter last year [1] - Earnings per share (EPS) rose to $5, up from $4 in the previous year, indicating strong profitability [1] Market Position - The company has strengthened its market position, capturing an additional 5% market share in the technology sector [1] - Increased demand for its products and services has been attributed to the rise in remote work and digital transformation trends [1] Future Outlook - Analysts predict continued growth, with expectations of a 15% increase in revenue for the upcoming fiscal year [1] - The company plans to invest $2 billion in research and development to enhance its product offerings and maintain competitive advantage [1]

Core Viewpoint - Akari Therapeutics is changing the ratio of its American Depositary Shares (ADSs) to ordinary shares to comply with Nasdaq's minimum bid price requirement, effective March 31, 2026 [1][2]. Group 1: ADS Ratio Change - The new ratio will be one ADS representing eighty thousand (80,000) ordinary shares, changing from the previous ratio of one ADS representing two thousand (2,000) ordinary shares [1][2]. - Each ADS holder will need to exchange every forty ADSs for one new ADS [2]. - Deutsche Bank will facilitate the exchange of current ADSs for new ADSs, and there will be no change to Akari's underlying ordinary shares [2]. Group 2: Fractional ADSs - No fractional new ADSs will be issued; instead, fractional entitlements will be aggregated and sold, with net cash proceeds distributed to ADS holders [3]. Group 3: Company Overview - Akari Therapeutics is focused on developing next-generation antibody drug conjugates (ADCs) with a unique payload, PH1, targeting RNA splicing [4]. - The lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and has shown significant activity in preclinical studies, with potential synergy with checkpoint inhibitors [4]. - Akari is also developing AKTX-102, targeting CEACAM5, leveraging the proprietary PH1 payload for differentiated tumor cell killing and immune activation [4].

Core Insights - Akari Therapeutics has made significant strategic progress under the leadership of CEO Abizer Gaslightwala, focusing on the advancement of its proprietary PH1 ADC payload platform and the development of its lead program, AKTX-101 [2][3][4]. Strategic Developments - The company has sharpened its strategic focus and advanced the development of its PH1 ADC payload platform, positioning itself to transition into a clinical-stage biotechnology company [3]. - AKTX-101, the lead program, is a Trop2-targeted ADC utilizing the PH1 payload and a proprietary non-cleavable linker, with new preclinical data presented at major scientific conferences [4]. - A strategic manufacturing partnership with WuXi XDC has been established to support IND-enabling activities, aiming for IND or CTA submission for AKTX-101 by late 2026 or early 2027 [5]. Pipeline Expansion - Akari has introduced AKTX-102, targeting CEACAM5-expressing tumors, which aims to demonstrate the scalability of its "pipeline in a payload" strategy [6]. - The company has strengthened its intellectual property through multiple provisional patent filings related to the PH1 payload and its mechanisms [7]. Scientific Advancements - The PH1 payload is a spliceosome modulator designed to disrupt RNA splicing in cancer cells, showing significant preclinical activity and potential synergy with checkpoint inhibitors [8][9].

Core Insights - Akari Therapeutics has appointed Dr. Prafulla Gokhale to its Scientific Advisory Board, enhancing its expertise in oncology drug development as it advances its lead candidate AKTX-101 toward clinical trials [1][2][4] Company Overview - Akari Therapeutics is focused on developing next-generation antibody drug conjugates (ADCs) with a unique payload, PH1, which targets RNA splicing, differentiating it from conventional ADCs that use tubulin inhibitors or DNA-damaging agents [7] - The lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and has shown significant activity in preclinical studies, indicating prolonged survival compared to traditional ADCs [7] - The company is also developing AKTX-102, which targets CEACAM5, a tumor antigen expressed across multiple solid tumors, leveraging the same PH1 payload for enhanced therapeutic effects [7] Dr. Prafulla Gokhale's Role - Dr. Gokhale brings over 20 years of experience in preclinical oncology drug discovery and development, having previously led pharmacology teams at major pharmaceutical companies [4] - His expertise in experimental therapeutics and translational oncology is expected to strengthen Akari's clinical strategies for AKTX-101, ensuring a data-driven approach as the company prepares for first-in-human studies [2][6] Mechanism of Action - The PH1 payload is designed to modulate spliceosomes, disrupting RNA splicing within cancer cells, which has been shown to induce cancer cell death while engaging both innate and adaptive immune responses [5][7] - Preclinical models indicate that AKTX-101 may work synergistically with checkpoint inhibitors, enhancing its therapeutic potential [7]

Core Viewpoint - Akari Therapeutics has appointed Dr. Olga Anczukow to its Scientific Advisory Board, enhancing its expertise in RNA biology and cancer research, which is crucial for the development of next-generation therapeutics [1][2][4] Company Overview - Akari Therapeutics is an oncology biotechnology company focused on developing antibody drug conjugates (ADCs) with a unique payload, PH1, that targets RNA splicing in cancer cells [9] - The lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and utilizes a proprietary linker to deliver the PH1 payload directly into tumors, minimizing off-target effects [9] - AKTX-101 has shown significant activity in preclinical studies, demonstrating prolonged survival compared to traditional ADCs and potential synergy with checkpoint inhibitors [9] Dr. Olga Anczukow's Background - Dr. Anczukow is a recognized leader in RNA biology and cancer research, currently serving as an Associate Professor at The Jackson Laboratory for Genomic Medicine and a Co-Program Leader at the NCI-designated Jackson Laboratory Cancer Center [4][6] - Her research focuses on alternative RNA splicing and its misregulation in cancer, contributing to tumor initiation, progression, and therapeutic resistance [4][6] - Dr. Anczukow's previous work includes significant contributions to understanding breast cancer genetics and the role of RNA splicing in cancer biology [5][6] Research and Development Focus - The company aims to leverage Dr. Anczukow's expertise to shape research strategy and evaluate emerging scientific opportunities, particularly in RNA-targeted treatments [2][4] - Akari's innovative ADC discovery platform allows for the generation and optimization of ADC candidates tailored to specific antigen targets [9] - The ongoing research at The Jackson Laboratory integrates various methodologies to investigate how cancer cells adapt their splicing programs to survive and evade therapy [6]

Core Insights - Akari Therapeutics is set to present at the 2026 Biocom Global Partnering & Investor Conference, highlighting its focus on oncology biotechnology and antibody drug conjugates (ADCs) with novel immuno-oncology payloads [1][2]. Company Overview - Akari Therapeutics specializes in developing next-generation ADCs, particularly focusing on a unique payload, PH1, which targets RNA splicing [3]. - The lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and utilizes a proprietary linker to deliver the PH1 payload directly into tumors, minimizing off-target effects [3]. - PH1 is a spliceosome modulator designed to disrupt RNA splicing in cancer cells, showing potential to induce cancer cell death while activating both innate and adaptive immune responses [3]. - Preclinical studies indicate that AKTX-101 has significant activity and prolonged survival compared to traditional ADCs, with potential synergy when combined with checkpoint inhibitors [3]. - The company has initiated IND enabling studies for AKTX-101, aiming to start its First-In-Human trial by late 2026 or early 2027 [3]. - Akari is also developing AKTX-102, targeting CEACAM5, a tumor antigen expressed in various solid tumors, leveraging the PH1 payload for enhanced tumor cell killing and immune activation [3].

Advancing Antibody Drug Conjugates With Novel Immuno-Oncology Payloads Forward-Looking Statements This presentation includes expressed or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), about the Akari Therapeutics, Plc (the "Company") that involve risks and uncertainties relating to future events and the future performance of the Company. Actual events or re ...

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]